Where Feuerstein went wrong is in thinking that the proportion of patients who progressed according to primary-endpoint component X in the Satra arm vs the control arm was a valid estimator of time to progression according to component X in the Satra arm vs the control arm. This, of course, is mathematically nonsensical!
Got it. Thanks. But note that the proportion of patients whose death was the trigger for PFS is probably a good indicator of excess death due to the chemo itself. But I agree that the FDA will care more about overall death - i.e. it is ok to kill 10% of patients if you save 30%.
"The SPARC data to be presented at upcoming medical conferences will show that Satra had an excellent safety profile for a chemo drug—much superior to Taxotere and to other platinum drugs."
So are these data different than the safety data presented at the PCa conference a few weeks back? Those data were as expected for a platinum drug and had more toxicity than Taxotere. The oral is more convenient, so satraplatin will be used instead of other platinums but the side effect profile means it is no danger to Taxotere -- unless I missed something.
Market Data 
Markets 
AI
